Ziprasidone

CHEMBL708 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

412.9 g/mol

LogP

4.0

Phase

4

This atypical antipsychotic medication is used to treat schizophrenia and bipolar mania, working by blocking dopamine and serotonin receptors in the brain to reduce symptoms such as hallucinations, delusions, and mood instability. It can prolong the QT interval on an electrocardiogram, so a baseline heart tracing is recommended before starting, and it should not be combined with other drugs that have the same effect. It should be taken with food to ensure adequate absorption.

분자량

412.9000 g/mol

LogP

4.00

TPSA

76.70 Å²

리핀스키 5의 법칙

통과

치료 영역

Cardiovascular Disease Pain Management Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Gastroesophageal Reflux Disease Chronic Kidney Disease Stroke Hyperlipidemia Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Chronic Pain Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1

InChI

InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)

Molecular Formula

C21H21ClN4OS

HBD / HBA

1 / 5

회전 가능 결합

4

무거운 원자

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This atypical antipsychotic medication is used to treat schizophrenia and bipolar mania, working by blocking dopamine and serotonin receptors in the brain to reduce symptoms such as hallucinations, delusions, and mood instability. It can prolong the QT interval on an electrocardiogram, so a baseline heart tracing is recommended before starting, and it should not be combined with other drugs that have the same effect. It should be taken with food to ensure adequate absorption.

Yes, Ziprasidone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL708. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 60854. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Ziprasidone PillFYI에서

구조

핵심 데이터

분자식: C21H21ClN4OS
동의어: 2

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.